Hemophilic Siblings With Chronic Hepatitis C: Familial Aggregation of Spontaneous and Treatment-Related Viral Clearance

Gastroenterology

Volumn 131, Issue 3, 2006, Pages 757-764

  Fried, Michael W ^a   Kroner, Barbara L ^b   Preiss, Liliana R ^b   Wilhelmsen, Kirk ^a   Goedert, James J ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b RTI INTERNATIONAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN;

ARTICLE; CONTROLLED STUDY; HEMOPHILIA; HEPATITIS C; HEREDITY; HERITABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SIBLING; STATISTICAL SIGNIFICANCE;

EID: 33748117249     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.07.001     Document Type: Article

References (57)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
2. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340 (1999) 1228-1233
3. Fanning L., Kenny E., Sheehan M., Cannon B., Whelton M., O'Connell J., Collins J.K., et al. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Hepatology 29 (1999) 904-907
4. Wiese M., Berr F., Lafrenz M., Porst H., and Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 32 (2000) 91-96
5. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 123 (2002) 2082-2099
6. Fanning L.J. The Irish paradigm on the natural progression of hepatitis C virus infection: an investigation in a homogeneous patient population infected with HCV 1b (review). Int J Mol Med 9 (2002) 179-184
7. Di Bisceglie A.M. Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. Am J Med 107 (1999) S53-S55
8. Marcellin P., Martinot M., Boyer N., and Levy S. Treatment of hepatitis C patients with normal aminotransferases levels. Clin Liver Dis 3 (1999) 843-853
9. Seeff L.B., Buskell-Bales Z., Wright E.C., Durako S.J., Alter H.J., Iber F.L., Hollinger F.B., et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 327 (1992) 1906-1911
10. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., and Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002) 889-896
11. Kim W.R., Brown Jr. R.S., Terrault N.A., and El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 36 (2002) 227-242
12. Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N., Nolt K., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284 (2000) 450-456
13. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
14. Goedert J.J., Eyster M.E., Lederman M.M., Mandalaki T., De Moerloose P., White II G.C., Angiolillo A.L., et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 100 (2002) 1584-1589
15. Zhang M., Rosenberg P.S., Brown D.L., Preiss L., Konkle B.A., Eyster M.E., and Goedert J.J. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 107 (2006) 892-897
16. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., and Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34 (2001) 730-739
17. Goedert J.J., Hatzakis A., Sherman K.E., and Eyster M.E. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. J Infect Dis 184 (2001) 1202-1205
18. Eyster M.E., Diamondstone L.S., Lien J.M., Ehmann W.C., Quan S., and Goedert J.J. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 6 (1993) 602-610
19. Sulkowski M.S., and Thomas D.L. Hepatitis C in the HIV-infected person. Ann Intern Med 138 (2003) 197-207
20. Bataller R., North K.E., and Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37 (2003) 493-503
21. Hellier S., Frodsham A.J., Hennig B.J., Klenerman P., Knapp S., Ramaley P., Satsangi J., et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38 (2003) 1468-1476
22. Goyal A., Kazim S.N., Sakhuja P., Malhotra V., Arora N., and Sarin S.K. Association of TNF-β polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol 72 (2004) 60-65
23. Muhlbauer M., Bosserhoff A.K., Hartmann A., Thasler W.E., Weiss T.S., Herfarth H., Lock G., et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125 (2003) 1085-1093
24. Chevillard C., Moukoko C.E., Elwali N.E., Bream J.H., Kouriba B., Argiro L., Rahoud S., et al. IFN-γ polymorphisms (IFN-γ +2109 and IFN-γ +3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni). J Immunol 171 (2003) 5596-5601
25. Powell E.E., Edwards-Smith C.J., Hay J.L., Clouston A.D., Crawford D.H., Shorthouse C., Purdie D.M., et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31 (2000) 828-833
26. Bonkovsky H.L., Troy N., McNeal K., Banner B.F., Sharma A., Obando J., Mehta S., et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 37 (2002) 848-854
27. Bataller R., North K.E., and Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37 (2003) 493-503
28. Lander E., and Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11 (1995) 241-247
29. Wacholder S., Chanock S., Garcia-Closas M., El Ghormli L., and Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96 (2004) 434-442
30. Wacholder S., Rothman N., and Caporaso N. Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomarkers Prev 11 (2002) 513-520
31. Wacholder S., Chatterjee N., and Hartge P. Joint effect of genes and environment distorted by selection biases: implications for hospital-based case-control studies. Cancer Epidemiol Biomarkers Prev 11 (2002) 885-889
32. Thomas D.C., and Witte J.S. Point: population stratification: a problem for case-control studies of candidate-gene associations?. Cancer Epidemiol Biomarkers Prev 11 (2002) 505-512
33. Fried M.W., Peter J., Hoots K., Gaglio P.J., Talbut D., Davis P.C., Key N.S., et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 36 (2002) 967-972
34. Fried M.W. Management of hepatitis C in the hemophilia patient. Am J Med 107 (1999) S85-S89
35. Brettler D.B., Alter H.J., Dienstag J.L., Forsberg A.D., and Levine P.H. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 76 (1990) 254-256
36. Kroner B.L., Rosenberg P.S., Aledort L.M., Alvord W.G., and Goedert J.J. HIV-1 infection incidence among persons with hemophilia in the United States and Western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 7 (1994) 279-286
37. Goedert J.J., Kessler C.M., Aledort L.M., Biggar R.J., Andes W.A., White II G.C., Drummond J.E., et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 321 (1989) 1141-1148
38. Goedert J.J. Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with hemophilia, 2001-2003. Haemophilia 11 (2005) 516-528
39. Kroner B.L., Goedert J.J., Blattner W.A., Wilson S.E., Carrington M.N., and Mann D.L. Concordance of human leukocyte antigen haplotype-sharing, CD4 decline and AIDS in hemophilic siblings. Multicenter Hemophilia Cohort and Hemophilia Growth and Development Studies. AIDS 9 (1995) 275-280
40. Strachan T., and Read A.P. Human molecular genetics 2 (1999), Wiley and Sons, New York, NY
41. Almasy L., and Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 62 (1998) 1198-1211
42. Rybicki B.A., and Elston R.C. The relationship between the sibling recurrence-risk ratio and genotype relative risk. Am J Hum Genet 66 (2000) 593-604
43. Vogt M., Lang T., Frosner G., Klingler C., Sendl A.F., Zeller A., Wiebecke B., et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 341 (1999) 866-870
44. Lai M.E., Mazzoleni A.P., Argiolu F., De Virgilis S., Balestrieri A., Purcell R.H., Cao A., et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343 (1994) 388-390
45. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., Cheng J., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (2004) 872-874
46. Oleksyk T.K., Thio C.L., Truelove A.L., Goedert J.J., Donfield S.M., Kirk G.D., Thomas D.L., et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 6 (2005) 347-357
47. Thio C.L., Goedert J.J., Mosbruger T., Vlahov D., Strathdee S.A., O'Brien S.J., Astemborski J., et al. An analysis of tumor necrosis factor α gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. Genes Immun 5 (2004) 294-300
48. Thio C.L., Gao X., Goedert J.J., Vlahov D., Nelson K.E., Hilgartner M.W., O'Brien S.J., et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 76 (2002) 4792-4797
49. Knapp S., Yee L.J., Frodsham A.J., Hennig B.J., Hellier S., Zhang L., Wright M., et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 4 (2003) 411-419
50. Chen L., Borozan I., Feld J., Sun J., Tannis L.L., Coltescu C., Heathcote J., et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 (2005) 1437-1444
51. Houldsworth A., Metzner M., Rossol S., Shaw S., Kaminski E., Demaine A.G., and Cramp M.E. Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res 25 (2005) 271-276
52. Naito M., Matsui A., Inao M., Nagoshi S., Nagano M., Ito N., Egashira T., et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 40 (2005) 381-388
53. Matsuyama N., Mishiro S., Sugimoto M., Furuichi Y., Hashimoto M., Hijikata M., and Ohta Y. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 25 (2003) 221-225
54. Promrat K., McDermott D.H., Gonzalez C.M., Kleiner D.E., Koziol D.E., Lessie M., Merrell M., et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 124 (2003) 352-360
55. Luo S., Cassidy W., Jeffers L., Reddy K.R., Bruno C., and Howell C.D. Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy. Clin Gastroenterol Hepatol 3 (2005) 499-506
56. Theodore D., Fried M.W., Kleiner D.E., Kroner B.L., Goedert J.J., Eyster M.E., Faust S.P., et al. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia 10 (2004) 413-421
57. Merikangas K.R., and Risch N. Genomic priorities and public health. Science 302 (2003) 599-601